Development and validation of the medication-based disease burden index.

BACKGROUND

Medication lists offer an alternative source of data on comorbidities and disease burden.

OBJECTIVE

To develop and validate the Medication-Based Disease Burden Index (MDBI).

METHODS

A list of medications corresponding to the leading causes of global death was pilot tested and finalized by an expert panel. The resulting index was tested on drug regimens of patients at risk of medication misadventure. Criterion validity of the index was established against Charlson's index and Chronic Disease Score (CDS). Sensitivity, specificity, predictive validity, convergent and discriminant validity, and interrater and test-retest reliabilities of the index were also assessed.

RESULTS

The MDBI consisting of specific medications for 20 chronic medical conditions and corresponding disability weightings was developed. The MDBI was tested on 317 patients with mean +/- SD Charlson's index scores of 2.8 +/- 2.2 and CDS scores of 7.3 +/- 2.8. Mean MDBI scores (0.33 +/- 0.28) demonstrated significant correlations with Charlson's index scores (r = 0.31; p < 0.001) and CDS (r = 0.53; p < 0.001). MDBI had satisfactory sensitivity and high specificity. Age of the patients and number of medications had significant correlation with the MDBI scores, but the MDBI scores were not significantly different in males and females. MDBI scores could successfully predict death and planned or unplanned readmissions (OR = 4.7, 95% CI 1.4 to 15.5; p = 0.01). MDBI demonstrated high inter-rater (intraclass correlation coefficient [ICC] = 0.99) and test-retest reliabilities (ICC = 0.98).

CONCLUSIONS

Initial testing suggests that MDBI could offer an alternative low-cost and convenient method for quantifying disease burden and predicting health outcomes.